Foundation Medicine, Inc.

Vanderbilt University

Vincent A Miller

Philip James Stephens

Doron Lipson

Jeffrey S Ross

Matthew J Hawryluk

Gary Palmer

Roman Yelensky

Garrett Michael Frampton

Jie He

Maureen T Cronin

Siraj Mahamed Ali

Mary Patricia Lancelotta

Michael Pellini

James Xin Sun

David Fabrizio

Douglas B Johnson

Jeffrey Alan Sosman

Christine Marie Lovly

Mary Pat Lancelotta

Methods and compositions for treating cholangiocarcinoma.

Methods of treating cholangiocarcinoma

Novel mutant ESR1 molecules and uses are disclosed.

Estrogen receptor mutations and uses thereof

Provided are systems and methods for capturing outcome information associated with various cancer treatments. The system facilitates capture and analysis of cancer treatment information and associated outcome information. The treatment and outcome information can include genomic analysis and information on treatment of different cancers. The system can store and analyze any one or more of: tumor type, genomic alterations (e.g., genes and associated alterations, gene sequence mutations, alterations, amplifications, deletions, etc.), and treatment data (including, for example, treatments targeted to specific genes and/or genomic alterations). Users of the outcome system can supply and use the treatment and outcome information to facilitate diagnosis and therapy decisions. User interfaces within the system can be configured to allow users to easily locate outcome information associated with particular treatments of tumors having certain genomic alterations.

System and method for outcome tracking and analysis

Methods and compositions for treating cancer such as melanomas are disclosed.

Methods of treating cancer

Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.

NTRK1 fusion molecules and uses thereof

A system for tracking and analyzing cancer treatment and outcome information includes a user interface (UI) component for allowing selection of an alteration, an affected gene, an affected pathway, a tumor type, and/or a treatment; a processor configured to receive treatment information and outcome information associated with a patient population; organize the treatment information and the outcome information into at least one tuple; and generate outcome summary information; and an analysis component configured to compare a current patient record for a current patient to existing treatment information for the patient population, identify similar patients in the patient population based on information in the current patient record, and filter a grouping of similar patients; the processor is further configured to display, on the UI component, the outcome summary information; enable navigation within the treatment and outcome information; and identify, based on the outcome information, an appropriate treatment for the current patient.

Growing community of inventors

West Orange, NJ, United States of America

Vincent A Miller